MetaVia locks down global patent shield for metabolic drug candidate Vanoglipel

The protections extend through at least 2035, with the potential for further extensions

NewcelX and Eledon join forces to advance potential Type 1 diabetes cure

The collaboration will leverage this clinical experience to inform NCEL-101 development, streamline regulatory pathways, and potentially accelerate timelines for achieving durable graft survival comparable to donor human islets

EnteroBiotix completes enrollment in landmark microbiome trial for stem cell transplant patients

The MAST trial is designed to test whether a single dose of pre-emptive, orally administered EBX-102-02 can protect and restore microbial diversity during transplantation

Kainova reports positive Phase I results for receptor antagonist targeting advanced tumors

Phase I EPRAD study of DT-9081 demonstrated a favorable safety profile

FDA nod to first treatment for rare genetic brain disorder

The approval comes after a systematic review of published literature

Lonza expands manufacturing pact with Genetix to meet rising demand for gene therapy ZYNTEGLO

Lilly expands affordable access to diabetes & obesity medicines under new medicare programme

Starting January 1, 2027, Lilly’s Zepbound (tirzepatide), Mounjaro (tirzepatide), and orforglipron, if approved, will be available through participating Medicare Part D plans

Alembic enters US branded market with first sales of Pivya UTI treatment

Pivya is Alembic’s first branded pharmaceutica product in the US and is being marketed through Alembic Therapeutics LLC

Lonza to set up Global Capability Centre in Hyderabad

Hyderabad emerged as Lonza’s preferred destination after an extensive global evaluation process

Sea Urchin spines inspire breakthrough sensor that detects water flow instantly

Their findings, published in the journal Nature, reveal that the spines’ unique porous internal structure allows them to convert water movement into measurable electrical signals